Brokerages Set Krystal Biotech, Inc. (NASDAQ:KRYS) Price Target at $220.00

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) have earned a consensus recommendation of “Buy” from the eight research firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $220.00.

Several equities research analysts have recently weighed in on KRYS shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 target price on shares of Krystal Biotech in a research note on Thursday, February 20th. Chardan Capital increased their target price on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a research note on Thursday, February 20th. HC Wainwright reissued a “buy” rating and issued a $221.00 target price on shares of Krystal Biotech in a research note on Friday, February 28th. Jefferies Financial Group began coverage on shares of Krystal Biotech in a research note on Wednesday, March 5th. They issued a “buy” rating and a $245.00 target price on the stock. Finally, Citigroup raised their price target on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research note on Thursday, February 20th.

Insider Activity

In other news, CAO Kathryn Romano sold 750 shares of the business’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the sale, the chief accounting officer now owns 12,604 shares in the company, valued at approximately $2,208,472.88. The trade was a 5.62 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the sale, the insider now owns 1,463,711 shares of the company’s stock, valued at approximately $260,233,178.69. This represents a 1.68 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 14.10% of the company’s stock.

Institutional Investors Weigh In On Krystal Biotech

Several large investors have recently modified their holdings of KRYS. Wilmington Savings Fund Society FSB purchased a new position in shares of Krystal Biotech in the 3rd quarter worth approximately $40,000. GF Fund Management CO. LTD. purchased a new position in shares of Krystal Biotech in the 4th quarter worth approximately $95,000. Huntington National Bank grew its position in shares of Krystal Biotech by 97.6% in the 3rd quarter. Huntington National Bank now owns 573 shares of the company’s stock worth $104,000 after buying an additional 283 shares during the last quarter. Covestor Ltd grew its position in shares of Krystal Biotech by 972.7% in the 4th quarter. Covestor Ltd now owns 708 shares of the company’s stock worth $111,000 after buying an additional 642 shares during the last quarter. Finally, KBC Group NV grew its position in shares of Krystal Biotech by 25.9% in the 3rd quarter. KBC Group NV now owns 642 shares of the company’s stock worth $117,000 after buying an additional 132 shares during the last quarter. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Stock Down 0.8 %

KRYS stock opened at $187.15 on Monday. Krystal Biotech has a 52 week low of $141.72 and a 52 week high of $219.34. The company has a fifty day simple moving average of $166.67 and a two-hundred day simple moving average of $173.56. The firm has a market capitalization of $5.39 billion, a P/E ratio of 62.59 and a beta of 0.87.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, beating the consensus estimate of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business had revenue of $91.10 million for the quarter, compared to the consensus estimate of $91.35 million. During the same quarter in the prior year, the firm posted $0.30 earnings per share. The business’s revenue for the quarter was up 116.4% on a year-over-year basis. As a group, analysts anticipate that Krystal Biotech will post 6.14 EPS for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).